These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26065842)

  • 21. Effects of Sarcomere Activators and Inhibitors Targeting Myosin Cross-Bridges on Ca
    Halas M; Langa P; Warren CM; Goldspink PH; Wolska BM; Solaro RJ
    Mol Pharmacol; 2022 May; 101(5):286-299. PubMed ID: 35236770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The myosin activator omecamtiv mecarbil: a promising new inotropic agent.
    Nánási P; Váczi K; Papp Z
    Can J Physiol Pharmacol; 2016 Oct; 94(10):1033-1039. PubMed ID: 27322915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Adams KF; Anand I; Arias-Mendoza A; Biering-Sørensen T; Böhm M; Bonderman D; Cleland JGF; Corbalan R; Crespo-Leiro MG; Dahlström U; Echeverria LE; Fang JC; Filippatos G; Fonseca C; Goncalvesova E; Goudev AR; Howlett JG; Lanfear DE; Li J; Lund M; Macdonald P; Mareev V; Momomura SI; O'Meara E; Parkhomenko A; Ponikowski P; Ramires FJA; Serpytis P; Sliwa K; Spinar J; Suter TM; Tomcsanyi J; Vandekerckhove H; Vinereanu D; Voors AA; Yilmaz MB; Zannad F; Sharpsten L; Legg JC; Varin C; Honarpour N; Abbasi SA; Malik FI; Kurtz CE;
    N Engl J Med; 2021 Jan; 384(2):105-116. PubMed ID: 33185990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early sensitization of myofilaments to Ca2+ prevents genetically linked dilated cardiomyopathy in mice.
    Alves ML; Warren CM; Simon JN; Gaffin RD; Montminy EM; Wieczorek DF; Solaro RJ; Wolska BM
    Cardiovasc Res; 2017 Jul; 113(8):915-925. PubMed ID: 28379313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.
    Teerlink JR; Felker GM; McMurray JJ; Solomon SD; Adams KF; Cleland JG; Ezekowitz JA; Goudev A; Macdonald P; Metra M; Mitrovic V; Ponikowski P; Serpytis P; Spinar J; Tomcsányi J; Vandekerckhove HJ; Voors AA; Monsalvo ML; Johnston J; Malik FI; Honarpour N;
    Lancet; 2016 Dec; 388(10062):2895-2903. PubMed ID: 27914656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of tropomyosin-κ induces dilated cardiomyopathy and depresses cardiac myofilament tension by mechanisms involving cross-bridge dependent activation and altered tropomyosin phosphorylation.
    Karam CN; Warren CM; Rajan S; de Tombe PP; Wieczorek DF; Solaro RJ
    J Muscle Res Cell Motil; 2011 Mar; 31(5-6):315-22. PubMed ID: 21221740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The structural basis of alpha-tropomyosin linked (Asp230Asn) familial dilated cardiomyopathy.
    Lynn ML; Tal Grinspan L; Holeman TA; Jimenez J; Strom J; Tardiff JC
    J Mol Cell Cardiol; 2017 Jul; 108():127-137. PubMed ID: 28600229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A myosin activator improves actin assembly and sarcomere function of human-induced pluripotent stem cell-derived cardiomyocytes with a troponin T point mutation.
    Broughton KM; Li J; Sarmah E; Warren CM; Lin YH; Henze MP; Sanchez-Freire V; Solaro RJ; Russell B
    Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H107-17. PubMed ID: 27199119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.
    Malik FI; Hartman JJ; Elias KA; Morgan BP; Rodriguez H; Brejc K; Anderson RL; Sueoka SH; Lee KH; Finer JT; Sakowicz R; Baliga R; Cox DR; Garard M; Godinez G; Kawas R; Kraynack E; Lenzi D; Lu PP; Muci A; Niu C; Qian X; Pierce DW; Pokrovskii M; Suehiro I; Sylvester S; Tochimoto T; Valdez C; Wang W; Katori T; Kass DA; Shen YT; Vatner SF; Morgans DJ
    Science; 2011 Mar; 331(6023):1439-43. PubMed ID: 21415352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orthophosphate increases the efficiency of slow muscle-myosin isoform in the presence of omecamtiv mecarbil.
    Governali S; Caremani M; Gallart C; Pertici I; Stienen G; Piazzesi G; Ottenheijm C; Lombardi V; Linari M
    Nat Commun; 2020 Jul; 11(1):3405. PubMed ID: 32636378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The dilated cardiomyopathy-causing mutation ACTC E361G in cardiac muscle myofibrils specifically abolishes modulation of Ca(2+) regulation by phosphorylation of troponin I.
    Vikhorev PG; Song W; Wilkinson R; Copeland O; Messer AE; Ferenczi MA; Marston SB
    Biophys J; 2014 Nov; 107(10):2369-80. PubMed ID: 25418306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.
    Greenberg BH; Chou W; Saikali KG; Escandón R; Lee JH; Chen MM; Treshkur T; Megreladze I; Wasserman SM; Eisenberg P; Malik FI; Wolff AA; Shaburishvili T
    JACC Heart Fail; 2015 Jan; 3(1):22-29. PubMed ID: 25453536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C.
    Mamidi R; Gresham KS; Li A; dos Remedios CG; Stelzer JE
    J Mol Cell Cardiol; 2015 Aug; 85():262-72. PubMed ID: 26100051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac myosin activation part 1: from concept to clinic.
    Malik FI; Morgan BP
    J Mol Cell Cardiol; 2011 Oct; 51(4):454-61. PubMed ID: 21616079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DCM-related tropomyosin mutants E40K/E54K over-inhibit the actomyosin interaction and lead to a decrease in the number of cycling cross-bridges.
    Bai F; Groth HL; Kawai M
    PLoS One; 2012; 7(10):e47471. PubMed ID: 23077624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new approach to inotropic therapy in the treatment of heart failure: cardiac myosin activators in treatment of HF.
    Garg V; Frishman WH
    Cardiol Rev; 2013; 21(3):155-9. PubMed ID: 23018669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional assays reveal the pathogenic mechanism of a de novo tropomyosin variant identified in patient with dilated cardiomyopathy.
    Barrick SK; Garg A; Greenberg L; Zhang S; Lin CY; Stitziel NO; Greenberg MJ
    J Mol Cell Cardiol; 2023 Mar; 176():58-67. PubMed ID: 36739943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omecamtiv Mecarbil Abolishes Length-Mediated Increase in Guinea Pig Cardiac Myofiber Ca
    Gollapudi SK; Reda SM; Chandra M
    Biophys J; 2017 Aug; 113(4):880-888. PubMed ID: 28834724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [CLINICAL EFFICACY OF A REPRESENTATIVE OF A NEW CLASS OF INOTROPIC AGENTS - THE DIRECT ACTIVATOR OF MYOSIN OF CARDIOMYOCYTES OMECAMTIV MECARBIL IN HEART FAILURE WITH A REDUCED EJECTION FRACTION].
    Kravchenko I; Rudyk I; Medentseva O
    Georgian Med News; 2021 Sep; (318):165-171. PubMed ID: 34628401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of the dilated cardiomyopathy-causing Glu40Lys TPM1 mutation on actin-myosin interactions during the ATPase cycle.
    Borovikov YS; Avrova SV; Karpicheva OE; Robinson P; Redwood CS
    Biochem Biophys Res Commun; 2011 Aug; 411(3):496-500. PubMed ID: 21741356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.